ORX Orexo AB (publ)

0.0984USD1.000 SEK · STO-0.60%Mkt Cap: 5.52M USDP/E: —

Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products in…

Institutional holders3 on file

Key Statistics

Company
Market Cap5.52M USD
Enterprise Value-10.91M USD
Revenue (TTM)1.23M USD
Gross Profit1.13M USD
Net Income (TTM)62.93M USD
Revenue/Share0.04 USD
Last Price0.0984 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees55
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINSE0000736415
Valuation
P/E (Trailing)—
P/E (Forward)-0.23
PEG13.07
EV/EBITDA0.33
EV/Revenue-8.87
P/S4.49
P/B0.20
EPS (TTM)-0.78 USD
EPS (Forward)-0.42 USD
52W Range
0.07871% of range3.543
52W High3.543 USD
52W Low0.0787 USD
Profitability
Gross Margin44.23%
Oper. Margin-2943.20%
EBITDA Margin0.00%
Profit Margin2458.85%
ROE130.31%
ROA49.07%
ROIC-488.67%
ROCE-34.47%
Growth
Revenue Growth-83.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.23M USD
CapEx (TTM)—
FCF Margin-1012.40%
FCF Yield-225.64%
Net Debt-14.37M USD
Net Debt/EBITDA0.44
Net Debt/FCF—
Balance Sheet
Debt/Equity1.00
Current Ratio1.50
Quick Ratio1.42
Book Value/Sh0.50 USD
Cash/Share0.43 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)2.608 USD
Upside (mean)+2550.0%
Target Range2.608 USD – 2.608 USD
# Analysts1
Ownership
Shares Out.56.09M
Float22.55M
Insiders10.13%
Institutions45.81%
Technical
SMA 500.7065 (-86.1%)
SMA 2001.666 (-94.1%)
Beta1.03
S&P 52W Chg12.00%
Avg Vol (30d)616.74K
Avg Vol (10d)1.16M
Technical Indicators
RSI (14)11.1
MACD-1.7766
MACD Signal-1.9802
MACD Hist.+0.2036
BB Upper0.5923 USD
BB Middle0.2351 USD
BB Lower-0.1221 USD
BB Width303.84%
ATR (14)0.0424 USD
Vol Ratio (20d)0.80x

About Orexo (STO: ORX)

›

Orexo (STO: ORX) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 55 employees.

The shares were at 1.000 SEK on 19 November 2026, down 96.4% over 52 weeks. Its 52-week range is 0.8000 SEK to 36.00 SEK: the price is 97.2% below the high and 25.0% above the low.

Its market capitalisation is 56.09M SEK.

Orexo reports return on equity of 130.3% and revenue down 83.3% year over year.

It holds more cash than debt, a net cash position of 146.00M SEK. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. The next earnings report is expected on 4 February 2027.